www.diseases-diagnosis.com Homepage Diseases Symptoms Diseases Diagnosis Diseases Treatment Diseases Living Care Diseases Prevention Diseases Research
March 26, 2016
Table of Contents

1 Introduction



Actavis is an international generic pharmaceutical company based in Iceland that was founded in 1956 as Pharmaco. Listed on the Icelandic Stock Exchange until 2007, it was taken private by Novator Partners, an investment vehicle of the chairman Bj??rg??lfur Thor Bj??rg??lfsson.

In the late 1990s, Actavis employed fewer than one hundred people and operated solely in the Icelandic market. In 1999, Actavis acquired Bulgarian rival Balkanpharma, beginning a period of substantial growth.

Since then, Actavis has made 25 acquisitions and now operates in 40 countries and employees over 11,000 people. The Group has one of the broadest portfolios in the generics sector with over 650 products on the market, in addition to over 400 products in the development pipeline and in registration.

Actavis is currently among the five largest generic pharmaceutical companies in the world. Its turnover for 2006 is predicted to be 1,390 million euros, compared to 56 million euros in 1999.

The chairman of the company is Icelandic businessman Bj??rg??lfur Thor Bj??rg??lfsson. Robert Wessman became President and CEO of Actavis following the company???s merger with Delta in 2002, where he had served as CEO since 1999. A business graduate and lecturer at the University of Iceland, Wessman worked previously at Icelandic transportation company Samskip, advancing to the post of CEO in Germany. Robert is also a Board Member of the Icelandic Chamber of Commerce.

On the 24th of November 2006, Actavis announced the departure of Svafa Gronfeldt, Deputy to the CEO. She leaves Actavis to pursue a new position as Dean of Reykjavik University. Sigur??ur ??li ??lafson takes her place as Deputy to the CEO. On 5 August 2008, R??bert Wessmann stepped down as the CEO to focus on his personal investments through his company, Salt Investments. Sigur??ur ??li ??lafsson took his place as CEO.

On the 23rd June 2010 it was announced that Sigurdur Oli Olafsson will be stepping down as CEO and Claudio Albrecht, former CEO of Ratiopharm and an experienced consultant to the pharmaceutical industry has been appointed as the Group???s CEO.

One noteworthy service offered by Actavis is the " Evidence-based medicine (EBM) Research Service". The service is free of charge for registered Medical Doctors (MD's) and is offered out of Austria and Switzerland. A registered MD can send a research inquiry to an Actavis team of specialists from Austrian universities, who will research the topic and provide a research report to back to the MD.

  • Actavis corporate website

  • Actavis Malta

  • Actavis Bulgaria

  • Actavis Serbia

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Actavis".

Last Modified:   2010-11-29

All informatin on the site is © www.diseases-diagnosis.com 2002-2011. Last revised: January 2, 2011
Are you interested in our site or/and want to use our information? please read how to contact us and our copyrights.
To let us provide you with high quality information, you can help us by making a more or less donation: